Endocrinology

 
SGLT-2 Inhibitors Belong to Patients, Not a Specialty or Primary Care: Experts Discuss
May 18, 2022

Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed.

Tailored Diabetes Risk Assessment May Reduce Racial/Ethnic Disparities in Diagnosis
May 11, 2022

Lowering thresholds for BMI value and age of first diabetes screening among large US minority populations could greatly increase rates of diagnosis and improve care.

Interview: Delay in Second-line T2D Treatment Among Younger US Veterans Sparks Investigator Concern
May 10, 2022

HbA1c levels over time were found higher at initiation of second-line treatment in veterans aged 55 years and younger, a trend unsettling to a new study's lead author.

Prototype of “Multi-tasking” Wearable Found to Continuously Monitor Glucose, Alcohol, and Lactate Levels
May 10, 2022

The wearable device allows users to monitor their health while also performing their regular daily activities.

Latest Advances in CGM Technology: A 5-question Quiz
May 06, 2022

SAMPLE: What was the first FDA-approved CGM system to include a fully implantable sensor to detect glucose?

SGLT-2 Inhibitor and GLP-1 Receptor Agonist Prescribing Trends 2015-2020
May 04, 2022

PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.

Novel Once-Weekly Insulin Icodec Found Superior vs Insulin Degludec in Reducing HbA1c in Type 2 Diabetes
April 29, 2022

The ONWARDS 2 trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 26 with insulin icodec vs insulin degludec.

Newly Developed Polygenic Risk Scores May Assist Decision-making in Primary Care
April 21, 2022

Researchers developed polygenic risk scores for 6 common diseases and informational resources to help primary care physicians incorporate them into clinical practice.

Finerenone Consistently Reduced Cardiorenal Risk Regardless of ASCVD History in FIDELITY
April 08, 2022

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.

New Diabetes Device Comparison Platform Supports Clinical Decision-making, Prescribing
April 08, 2022

DiabetesWise Pro, created at Stanford University, provides an unbranded, unbiased guide to matching diabetes technology to patient needs, access, and lifestyle.